δ-Opioid Receptor Activation Inhibits Ferroptosis by Activating the Nrf2 Pathway in MPTP-Induced Parkinson Disease Models

Figure 5

DOR activation inhibits ferroptosis in MPTP-treated PC12 cells. (a) MDA and 4-HNE levels in PC12 cells after different treatments, as detected using the MDA and 4-HNE assay kits. (b) Representative western blots of Nrf2, GPX4, and SLC7a11, and quantitative analysis of the protein levels of Nrf2, GPX4, and SLC7a11. (c) Mitochondrial membrane potential as assessed using JC-1 staining of PC12 cells subjected to different treatments (scale bar = 50 μm). Data are presented as the mean ± S.E. of three independent experiments. ; ; ns, . DOR, DOR, δ-opioid receptor; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MDA, malondialdehyde; 4-HNE, 4-hydroxynonenal; GPX4, glutathione peroxidase 4; DADLE, [D-Ala², D-Leu⁵]-enkephalin; ns, not significant; C, control; M, MPTP; F, ferrostatin-1; D, DADLE; N, naltrindole.

(a)

(b)

(c)